Nov 12 (Reuters) - IMV Inc IMV.TO :
* IMV INC. ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE
* IMV INC - DPX-COVID-19 PHASE 1/2 TRIAL IS EXPECTED TO BE APPROVED AND INITIATED BEFORE END OF 2020.
* IMV INC - ENTERED COLLABORATION WITH GLOBAL MANUFACTURING PARTNER AND INITIATED TRANSFER, SCALE-UP ACTIVITIES OF DPX-COVID-19
* IMV INC - EXPECTS CURRENT CASH POSITION WILL BE SUFFICIENT TO FUND OPERATIONS FOR MORE THAN NEXT 12 MONTHS
* IMV INC - QTRLY LOSS PER SHARE C$0.13